IGF-1 LR3 and HGH are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
One axis, two positions
The clearest way to understand these two compounds is to place them on a single signalling chain. Growth hormone sits at the top: it binds receptors across many tissues and, crucially, drives the liver to synthesise insulin-like growth factor 1 (IGF-1), the mediator that carries much of the downstream anabolic signal. IGF-1 LR3 is a long-acting analogue of that mediator — it skips the hormone step entirely and activates the IGF-1 receptor directly. In other words, this is the hormone versus its messenger. Read our full profiles of HGH and IGF-1 LR3 for the underlying detail; here we set the two side by side.
| IGF-1 LR3 | HGH | |
|---|---|---|
| Class / peptide type | Long-acting IGF-1 analogue | Recombinant polypeptide hormone (somatropin) |
| Primary target | IGF-1 receptor (IGF-1R) — direct | Growth hormone receptor (GHR); IGF-1 release downstream |
| Structure / MW | 83 aa · ~9,111 Da · Arg3 substitution + 13-aa N-terminal extension | 191 aa · ~22,124 Da · sequence-identical to pituitary GH |
| Half-life | ~20–30 hours | ~2–4 hours (subcutaneous) |
| Main research focus | IGF-1R pharmacology, muscle / bone / metabolic biology, cell culture | GH/IGF-1 axis, body-composition pharmacology, endocrine signalling |
| Regulatory status | Unregulated research compound; WADA-prohibited | Prescription-only medicine (multiple approvals); WADA-prohibited |
IGF-1 LR3: the downstream mediator, engineered to last
IGF-1 LR3 (Long Arg3 IGF-1) is a modified human IGF-1 analogue built around two structural changes: an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. Together these reduce the molecule's affinity for the IGF-binding proteins (IGFBP-1 through IGFBP-6) that normally sequester roughly 99% of circulating IGF-1. The result is a substantially larger bioavailable fraction, a half-life extended to around 20–30 hours — against roughly six hours for native IGF-1 — and about threefold greater potency at the IGF-1 receptor.
Mechanistically it binds and activates IGF-1R, a receptor tyrosine kinase that drives the PI3K/Akt/mTOR and Ras/MAPK cascades — the canonical mitogenic and anabolic pathways. Because IGFBPs in culture media bind native IGF-1 within minutes, the LR3 variant has become the de-facto standard reagent for IGF-1R activation studies in cell culture, holding receptor-activating concentrations across a full assay. Its published research spans satellite-cell proliferation and hypertrophy gene programmes in muscle, osteoblast signalling in bone, and glucose-metabolism work via insulin-receptor cross-talk. Researchers sourcing material can buy IGF-1 LR3 UK at ≥99% purity with a COA.
HGH: the hormone at the top of the chain
Recombinant human growth hormone (rhGH, somatropin) is a 191-amino-acid polypeptide identical in sequence to pituitary-derived growth hormone, produced by recombinant DNA technology in E. coli or mammalian cell-culture systems. It binds the growth hormone receptor, which dimerises on ligand binding and activates JAK2, signalling onward through STAT5, PI3K/Akt and Ras/MAPK. A major fraction of its downstream effect is indirect: rhGH drives hepatic IGF-1 synthesis, and that IGF-1 is the principal anabolic effector for skeletal growth and body-composition change.
Where IGF-1 LR3 acts on one receptor, HGH engages GHRs across hepatocytes, adipocytes, muscle and many other tissues — a broad, systemic signal rather than a targeted one. Its half-life is short at roughly 2–4 hours subcutaneously. It is also among the most clinically validated biologics in existence, with approvals across paediatric growth-hormone deficiency, Turner and Prader-Willi syndromes, adult GH deficiency and HIV-associated wasting, and it remains a primary tool for studying the GH/IGF-1 axis. For research-grade material you can buy HGH UK, supplied in multiple strengths at ≥99% purity.
What the differences mean in a research context
The core distinction is positional. HGH is upstream: it hits many tissues, works partly through second messengers, and delegates a large share of its anabolic effect to liver-derived IGF-1. IGF-1 LR3 is downstream: it is a long-acting version of that same mediator, activating IGF-1R directly and bypassing the hormone step, the pituitary loop and the IGFBP sequestration that limits native IGF-1. If a study wants to interrogate the IGF-1 arm in isolation, LR3 is the cleaner probe; if it wants the full systemic GH signal — GHR activation across tissues plus endogenous IGF-1 production — HGH is the tool.
Duration reinforces the split. IGF-1 LR3's engineered ~20–30-hour half-life makes it well suited to longer-duration receptor activation in culture, whereas HGH's ~2–4-hour clearance reflects a pulsatile hormone rather than a stabilised analogue. And the two occupy very different regulatory positions: HGH is a prescription-only medicine with a deep, mature evidence base, while IGF-1 LR3 remains an unregulated research compound. Both are WADA-prohibited and both, in this context, are strictly in vitro research reagents. They are complementary lenses on one pathway — one reading the hormone, the other its mediator.
The bottom line
HGH and IGF-1 LR3 are not rival versions of the same thing; they are two points on a single axis. HGH is the broad, upstream hormone that signals the liver to release IGF-1; IGF-1 LR3 is a long-acting, IGFBP-resistant analogue of that downstream mediator, acting directly at IGF-1R. Choose upstream breadth or downstream precision according to the question. For research-grade material, see our dedicated pages to buy IGF-1 LR3 UK and buy HGH UK, each ≥99% purity with a COA.